FUNCTIONAL ANALOGS OF THE ENEDIYNE TOXINS
烯乙炔毒素的功能类似物
基本信息
- 批准号:6375904
- 负责人:
- 金额:$ 19.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-07-01 至 2002-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The design and synthesis of functional models of the ene-diyne toxins is
the primary aim of this proposal. This will lead to the development of
selective cytotoxic drugs based on novel mechanisms of antibiotic
activity. The calicheamicins, esperimicins, and dynemycins are highly
toxic species with elegant mechanisms of activation which were not
anticipated before the natural structures were determined. With the
mechanisms now well supported by in vitro studies, it is possible to
design analogs which have all of the activation features, but will be
readily available in quantity, can be tailored to avoid peripheral
toxicity, and can have convenient tethers for conjugation with delivery
agents such as antibodies.
One model for calicheamicin has been demonstrated and will be elaborated
in the current grant period. The key triggering step is de-blocking of
the enol, and that operation can be designed to involve several different
biological mechanisms, including disulfide exchange as established for the
natural products. The result will be a simplified model for the "warhead"
or aglycone which can be triggered to produce high energy diradicals under
physiological conditions. A second general triggering mechanism will be
based on the same calicheamicin framework, but a different conformation
adjustment, boat-chair cyclohexane. A similar set of physiologically
compatible processes will be designed into the conformational trigger. A
collaborative effort with the Medical Research Division of American
Cyanamid will evaluate the new compounds as selective DNA cleavage agents
and arrange attachment of the more active derivatives to delivery systems,
including the monoclonal antibody conjugate now under study at Cyanamid
with the natural product itself.
An important aspect is the evaluation of various DNA delivery agents,
following up on the results with netropsin in the previous grant period.
The potency of the enediyne in DNA cleavage is very sensitive to
positioning on the DNA and proper design of the delivery agents is a
critical component.
本论文的目的是设计和合成烯二炔类毒素的功能模型,
这是该提案的主要目的。 这将导致发展
基于抗生素新机制的选择性细胞毒性药物
活动 卡奇霉素、esperimicins和动力霉素高度
具有优雅的激活机制的有毒物质,
在确定自然结构之前, 与
目前,体外研究充分支持了这一机制,
具有所有激活特征的设计类似物,
易于获得的数量,可以量身定制,以避免周边
毒性,并且可以具有方便的栓系物用于与递送结合
试剂如抗体。
加利车霉素的一个模型已经被证明,并将详细说明
在目前的补助期内。 关键的触发步骤是对
烯醇和操作可以被设计为涉及几种不同
生物学机制,包括二硫键交换,
天然产品。 其结果将是一个简化模型的“弹头”
或糖苷配基,其可以在
生理条件。 第二种通用触发机制将是
基于相同的加利车霉素框架,但不同的构象
调整,船椅环己烷。 一套类似的生理学
将相容过程设计到构象触发剂中。 一
与美国医学研究部合作,
氰胺将评估新化合物作为选择性DNA切割剂
并将活性更高的衍生物连接到递送系统上,
包括Cyanamid正在研究的单克隆抗体结合物
天然产品本身。
一个重要的方面是评估各种DNA递送剂,
跟踪上一个资助期内使用netropsin的结果。
烯二炔在DNA切割中的效力对以下因素非常敏感:
在DNA上的定位和递送剂的适当设计是
关键部件。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis of the amino sugar from C-1027.
从 C-1027 合成氨基糖。
- DOI:10.1021/ol010119s
- 发表时间:2001
- 期刊:
- 影响因子:5.2
- 作者:Semmelhack,MF;Jiang,Y;Ho,D
- 通讯作者:Ho,D
Conformational control in activation of an enediyne.
烯二炔活化中的构象控制。
- DOI:10.1021/ja036763e
- 发表时间:2003
- 期刊:
- 影响因子:15
- 作者:Semmelhack,MF;Wu,Lingyun;PascalJr,RobertA;Ho,DouglasM
- 通讯作者:Ho,DouglasM
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTIN F SEMMELHACK其他文献
MARTIN F SEMMELHACK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTIN F SEMMELHACK', 18)}}的其他基金
Inhibition of Interspecies Bacterial Quorum Sensing
种间细菌群体感应的抑制
- 批准号:
7488851 - 财政年份:2007
- 资助金额:
$ 19.62万 - 项目类别:
Inhibition of Interspecies Bacterial Quorum Sensing
种间细菌群体感应的抑制
- 批准号:
7320446 - 财政年份:2007
- 资助金额:
$ 19.62万 - 项目类别:
相似海外基金
Greatwall in replication stress/DNA damage responses and oral cancer resistance
长城在复制应激/DNA损伤反应和口腔癌抵抗中的作用
- 批准号:
10991546 - 财政年份:2024
- 资助金额:
$ 19.62万 - 项目类别:
The shielding role of the nuclear periphery against the genetic and non-genetic consequences of DNA damage (ChromoSENSOR)
核外围对 DNA 损伤的遗传和非遗传后果的屏蔽作用 (ChromoSENSOR)
- 批准号:
EP/Y027124/1 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
Research Grant
Aspartate beta-hydroxylase and DNA damage in chronic liver diseases
慢性肝病中的天冬氨酸 β-羟化酶和 DNA 损伤
- 批准号:
10667881 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
Role of DNA damage and cellular senescence in osteoarthritis pathophysiology
DNA 损伤和细胞衰老在骨关节炎病理生理学中的作用
- 批准号:
10801026 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
Impact of ATR's role in translesion synthesis on prevention of DNA damage induced mutagenesis and chromosomal instability
ATR 在跨损伤合成中的作用对预防 DNA 损伤诱导的突变和染色体不稳定性的影响
- 批准号:
10634852 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factor
转录、DNA 损伤和表观遗传学的界面:EWS-FLI1 转录因子的治疗脆弱性
- 批准号:
10718793 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
Investigating metabolism and DNA damage repair in uropathogenic Escherichia coli fluoroquinolone persisters
研究泌尿道致病性大肠杆菌氟喹诺酮类持续存在的代谢和 DNA 损伤修复
- 批准号:
10747651 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
Targeting the function of BRCA1 in the DNA damage response network.
靶向 DNA 损伤反应网络中 BRCA1 的功能。
- 批准号:
2879783 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
Studentship
Elucidation of the mechanism underlying cellular senescence and aging induced by the continuous DNA damage
阐明持续DNA损伤引起的细胞衰老和老化的机制
- 批准号:
22KJ0646 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma
TAZ 和 YAP 在 3D 基因组组织 DNA 损伤修复中的新作用以及胶质母细胞瘤的治疗耐药性
- 批准号:
10649830 - 财政年份:2023
- 资助金额:
$ 19.62万 - 项目类别:














{{item.name}}会员




